Literature DB >> 7061181

Disopyramide concentrations in saliva.

M L Aitio, R Virtanen, R Lammintausta.   

Abstract

The saliva and plasma concentrations of disopyramide and its main metabolite, mono-N-dealkyldisopyramide, and the protein binding of disopyramide were studied in ten healthy volunteers after a single oral 400-mg dose of disopyramide. Disopyramide had a concentration-dependent inhibitory effect on the salivary flow rate. The correlations between the salivary and total plasma concentrations of disopyramide (r = 0.774 linear, 0.890 exponential, p less than 0.0001), of the metabolite (r - 0.700, p less than 0.001), and between the salivary and free plasma concentrations of disopyramide (r = 0.785, p less than 0.001) were relatively good. The fraction of disopyramide not bound to plasma proteins varied from not measurable to 0.35, was concentration-dependent, and showed intersubject variation. The ratio of disopyramide concentrations in saliva and plasma (S/P ratio) varied from 0.08 to 1.51 and was highest when the salivary and plasma levels were high. No significant correlation existed between S/P ratio and salivary pH, and the correlation was poor (r = 0.546) between the measured salivary concentrations and those calculated theoretically. A wide interindividual variation was seen in all parameters measured. The salivary concentrations of disopyramide are unreliable for predicting the corresponding total or free plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061181

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  4 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.

Authors:  E Iisalo; L Aaltonen
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 4.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.